Download biomedica product list
Angiopoietin-2 predicts mortality in male ESKD patients on hemodialysis
Individuals suffering from end-stage kidney disease (ESKD) undergoing dialysis have significantly higher mortality rates compared to patients with non-ESKD of the same age. Approaches to assess mortality risk, which could enable tailored and effective care are needed (1).
Angiopoietin-2 (Ang2) is a protein that is crucial in pathological vascular restructuring and in the formation of new blood vessels (angiogenesis). These processes are active in ESKD patients and might contribute to the elevated mortality observed in this patient group.
Angiopoietin-2 predicts mortality in male ESKD patients on hemodialysis
In a recent multicenter prospective study Ang2 was measured in 340 hemodialysis (HD) patients with ESKD to predict overall mortality (2, 3). The patients were followed up for 5-years and blood samples and clinical data were collected at baseline. Ang2 serum levels were measured with a enzyme-linked immunosorbent assay (ELISA) from Biomedica.
Angiopoietin-2 predicts mortality in male ESKD patients on hemodialysis
The results of the study demonstrated that the risk of death was higher in male patients with elevated Ang2 levels than in female patients: Ang2 levels at baseline are independently associated with all cause mortality in male ESKR patients on HD.
Angiopoetin-2 can reliably be measured in serum or plasma samples with a conventional ELISA assay:
Human ANGIOPOIETIN-2 ELISA (cat. no. BI-ANG2)
- 20µl sample volume /well
- optimized for clinical samples – sample values provided
- kit includes ready to use standards and controls
- developed & manufactured by BIOMEDICA
- for serum/plasma/cell culture samples
- validation package available
BIOMEDICA ELISA assay
also available:
Mouse / rat ANGIOPOIETIN-2 ELISA (cat. no. BI-ANG2MR)
- 5µl sample volume /well
- kit control included
- sample values provided
Related Publications
- One- and 2-Year Mortality Prediction for Patients Starting Chronic Dialysis. Haapio M, Helve J, Grönhagen-Riska C, Finne P. Kidney Int Rep. 2017 Jun 24;2(6):1176-1185. doi: 10.1016/j.ekir.2017.06.019. PMID: 29270526; PMCID: PMC5733880.
- Angiopoietin-2 predicts all-cause mortality in male but not female end-stage kidney disease patients on hemodialysis. Chu C, Chen X, Hasan AA, Szakallova A, Krämer BK, Tepel M, Hocher B. Nephrol Dial Transplant. 2022 Jun 23;37(7):1348-1356. doi: 10.1093/ndt/gfab332. PMID: 34792167; PMCID: PMC9217660.
- Circulating angiopoietin-2 level is independently associated with all-cause mortality in male end-stage kidney disease patients on hemodialysis. Chu, Chang. Thesis, 2023-06-22T11:52:24Z.